ARQT News and Press, Arcutis Biotherapeutics Inc. From 09/02/21

WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases ...

Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitor Scalp and body psoriasis affects more than 8 million patients in the U.S. WESTLAKE VILLAGE, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-s...

WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and c...

Arcutis Biotherapeutics (NASDAQ:ARQT): Q2 GAAP EPS of -$0.84 beats by $0.13. Cash, cash equivalents, restricted cash, and marketable securities of $410.9M Press Release For further details see: Arcutis Biotherapeutics EPS beats by $0.13

Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of 2021 Initiated single pivotal Phase 3 trial of topical roflumilast foam in seborrheic dermat...

Eric McIntyre joins as Head of Investor Relations Amanda Sheldon joins as Head of Corporate Communications WESTLAKE VILLAGE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on develo...

The majority of patients with psoriasis have mild or moderate levels of disease The new method, PASI-high discrimination (PASI-HD), is designed for use in clinical trials evaluating novel topical treatment options for psoriasis Details of new approach published in Dermatology ...

Arcutis Biotherapeutics (ARQT) announces enrollment of the first patient in its single Phase 3 clinical trial evaluating topical roflumilast foam (ARQ-154) as a potential treatment for seborrheic dermatitis.The Phase 3 STRATUM (STudy of Roflumilast foam Applied Topically for the redUction of ...

Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitor Seborrheic dermatitis affects 10 million patients in the U.S. Potential first new topical treatment for seborrheic dermatitis in decades The Company anticipates topline data in the second or t...

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “A key debate on Arcutis’ lead asset, topical roflumilast, has been on its market potential given the likely difficult formul...